Search

Your search keyword '"Alexandra N. Heinloth"' showing total 3 results
Start Over Author "Alexandra N. Heinloth" Journal psychiatry research
3 results on '"Alexandra N. Heinloth"'

1. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder

Author

Roy H. Perlis, Katherine M. Ostbye, John P. Houston, Alexandra N. Heinloth, and Jared Kohler

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Genome-wide association study, Thiophenes, Duloxetine Hydrochloride, Catechol O-Methyltransferase, Polymorphism, Single Nucleotide, behavioral disciplines and activities, chemistry.chemical_compound, Sex Factors, Rating scale, Internal medicine, mental disorders, Hamd, medicine, Humans, Duloxetine, Psychiatry, Biological Psychiatry, Psychiatric Status Rating Scales, Depressive Disorder, Major, Catechol-O-methyl transferase, business.industry, fungi, Middle Aged, medicine.disease, Antidepressive Agents, Psychiatry and Mental health, nervous system, chemistry, Pharmacogenetics, Major depressive disorder, Female, sense organs, business, Genome-Wide Association Study
Abstract

Single-nucleotide and diplotype associations with 17-item Hamilton Depression Rating Scale (HAMD(17)) total score changes were examined, based on catechol-O-methyltransferase (COMT) rs165599 status in duloxetine-treated, self-identified white patients with major depressive disorder. COMT rs165737 and a diplotype containing COMT rs165599 and COMT rs165737 were associated with HAMD(17) total score changes.

Published
2011
Full Text
View/download PDF

2. Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder

Author

Peining Chen, John P. Houston, Alexandra N. Heinloth, Bonnie Fijal, Wei Zou, James M. Martinez, and Virginie Aris

Subjects
Adult, Male, medicine.medical_specialty, rs5569, Thiophenes, Duloxetine Hydrochloride, Catechol O-Methyltransferase, Gastroenterology, Polymorphism, Single Nucleotide, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Internal medicine, Surveys and Questionnaires, Genetic model, medicine, Duloxetine, Humans, Biological Psychiatry, rs6295, Depressive Disorder, Major, Framingham Risk Score, Norepinephrine Plasma Membrane Transport Proteins, Models, Genetic, medicine.disease, Antidepressive Agents, Psychiatry and Mental health, Endocrinology, Treatment Outcome, chemistry, Receptor, Serotonin, 5-HT1A, Major depressive disorder, Female, Psychology
Abstract

In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120 mg/d), a significant association of (P=0.020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed.

Published
2012

3. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients

Author

David H. Adams, John P. Houston, Bonnie Fijal, and Alexandra N. Heinloth

Subjects
Adult, Male, Olanzapine, medicine.medical_specialty, Candidate gene, medicine.drug_class, Atypical antipsychotic, Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, White People, Benzodiazepines, Young Adult, Double-Blind Method, Fluoxetine, Internal medicine, Dopamine receptor D2, medicine, Humans, skin and connective tissue diseases, Biological Psychiatry, Aged, Analysis of Variance, Dose-Response Relationship, Drug, Depression, Receptors, Dopamine D2, business.industry, Dopamine antagonist, Middle Aged, Prolactin, Hyperprolactinemia, Drug Combinations, Psychiatry and Mental health, Endocrinology, Female, sense organs, business, Antipsychotic Agents, Genome-Wide Association Study, medicine.drug
Abstract

In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results